Meeting
2018 Genitourinary Cancers Symposium
Abiraterone acetate in metastatic castration-resistant prostate cancer post-docetaxel: A “real-life” retrospective analysis of outcomes in a Brazilian public health institution.
Authors
Thais Caroline Menegasso Flores
CEPON Centro de Pesquisas Oncológicas de Florianópolis, Florianópolis, Brazil
Thais Caroline Menegasso Flores , Carolina da Silva Miranda Emerich , Facundo Zaffaroni , Márcio Debiasi , Carolina Dutra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 287)
DOI
10.1200/JCO.2018.36.6_suppl.287
Abstract #
287
Poster Bd #
A20
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Evan Y. Yu
Poster
2022 ASCO Annual Meeting
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.
First Author: Kambiz Rahbar
Poster
2021 ASCO Annual Meeting
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
First Author: Russell Kent Pachynski
Poster
2015 ASCO Annual Meeting
Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edwin M. Posadas